This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by White, C. M. Articles by Kluger, J. Search for Related Content PubMed PubMed Citation Articles by White, C. M. Articles by Kluger, J.

(Circulation. 2003;108:II-200.)
© 2003 American Heart Association, Inc.

Arrythmia Surgery

Intravenous Plus Oral Amiodarone, Atrial Septal Pacing, or Both Strategies to Prevent Post-Cardiothoracic Surgery Atrial Fibrillation: The Atrial Fibrillation Suppression Trial II (AFIST II)

C. Michael White, PharmD; Michael F. Caron, PharmD; James S. Kalus, PharmD; Heidi Rose, RN; Jessica Song, PharmD; Prabashni Reddy, PharmD; Robert Gallagher, MD; Jeffrey Kluger, MD

From the Divisions of Cardiology, Drug Information, and Cardiac Surgery at Hartford Hospital, Hartford, CT, and the School of Pharmacy, University of Connecticut, Storrs, CT.

Correspondence to Jeffrey Kluger, MD, Director, Arrhythmia Service, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102-5037. Phone: 860-545-2883; Fax: 860-545-2756; E-mail: Jkluger{at}harthosp.org

Background— The effect of a hybrid intravenous and oral prophylactic amiodarone regimen on postcardiothoracic surgery (CTS) atrial fibrillation (AF) is unknown. The impact of active atrial septal pacing on post-CTS AF has not been well characterized. In addition, the effect of using both amiodarone and atrial septal pacing together to prevent atrial fibrillation is unknown.

Methods and Results— Patients (n=160) were randomized to amiodarone or placebo and then to pacing or no pacing using a 2x2 factorial design. All therapies began within 6 hours post-CTS. Amiodarone was given by intravenous infusion for the first 24 hours (1050 mg total) followed by oral therapy for 4 postoperative days (4800 mg total). Atrial septal pacing was given for 96 hours. Amiodarone reduced the risk of AF by 43% and the risk of symptomatic AF by 68% (P=0.037 and P=0.019) versus placebo. Atrial septal pacing did not reduce AF or symptomatic AF incidence versus no pacing. The risk of post-CTS AF in the patients receiving amiodarone+pacing was lower than the placebo+no pacing and the placebo+pacing groups (57.9% and 60.5% reductions, P=0.047 and P=0.040, respectively).

Conclusions— Amiodarone given as both an intravenous and oral regimen is effective at reducing post-CTS AF but atrial septal pacing is ineffective. Combining amiodarone and pacing is better than placebo with or without pacing but not amiodarone alone.

Key Words: atrial fibrillation • amiodarone • pacemaker • artificial

This article has been cited by other articles:

				L. B. Mitchell, D. V. Exner, D. G. Wyse, C. J. Connolly, G. D. Prystai, A. J. Bayes, W. T. Kidd, T. Kieser, J. J. Burgess, A. Ferland, et al. Prophylactic Oral Amiodarone for the Prevention of Arrhythmias That Begin Early After Revascularization, Valve Replacement, or Repair: PAPABEAR: A Randomized Controlled Trial JAMA, December 28, 2005; 294(24): 3093 - 3100. [Abstract] [Full Text] [PDF]